Evidence map›Paper›PMID 36834783›Full record

ReviewInternational journal of molecular sciences2023

Research Status and Prospect of Non-Viral Vectors Based on siRNA: A Review.

Liangnan Tong, Danqing Liu, Zhiyue Cao, Nannan Zheng, Chenchen Mao, Shujuan Liu, Liangcan He, Shaoqin Liu

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Special Issue "Research Progress of Bioimaging Materials".International journal of molecular sciences · 2024
    Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Liangnan TongSchool of Material Science and Chemical Engineering, Harbin University of Science and Technology, Harbin 150040, China.
Danqing LiuSchool of Material Science and Chemical Engineering, Harbin University of Science and Technology, Harbin 150040, China.
Zhiyue CaoSchool of Life Science and Technology, Harbin Institute of Technology, Harbin 150001, China.
Nannan ZhengSchool of Medicine and Health, Harbin Institute of Technology, Harbin 150001, China.
Chenchen MaoDepartment of Electrical, Computer and Energy Engineering, University of Colorado Boulder, Boulder, CO 80309, USA.
Shujuan LiuSchool of Materials Science and Engineering, Harbin Institute of Technology, Harbin 150001, China.
Liangcan HeSchool of Life Science and Technology, Harbin Institute of Technology, Harbin 150001, China.ORCID 0000-0002-9415-9535
Shaoqin LiuSchool of Life Science and Technology, Harbin Institute of Technology, Harbin 150001, China.
Harbin Institute of Technology · CNHarbin University of Science and Technology · CNUniversity of Colorado Boulder · US

Funding

National Natural and Science Foundation of China Nos. 81901871, 52172085
6 · The paper itself

Abstract

Gene therapy has attracted much attention because of its unique mechanism of action, non-toxicity, and good tolerance, which can kill cancer cells without damaging healthy tissues. siRNA-based gene therapy can downregulate, enhance, or correct gene expression by introducing some nucleic acid into patient tissues. Routine treatment of hemophilia requires frequent intravenous injections of missing clotting protein. The high cost of combined therapy causes most patients to lack the best treatment resources. siRNA therapy has the potential of lasting treatment and even curing diseases. Compared with traditional surgery and chemotherapy, siRNA has fewer side effects and less damage to normal cells. The available therapies for degenerative diseases can only alleviate the symptoms of patients, while siRNA therapy drugs can upregulate gene expression, modify epigenetic changes, and stop the disease. In addition, siRNA also plays an important role in cardiovascular diseases, gastrointestinal diseases, and hepatitis B. However, free siRNA is easily degraded by nuclease and has a short half-life in the blood. Research has found that siRNA can be delivered to specific cells through appropriate vector selection and design to improve the therapeutic effect. The application of viral vectors is limited because of their high immunogenicity and low capacity, while non-viral vectors are widely used because of their low immunogenicity, low production cost, and high safety. This paper reviews the common non-viral vectors in recent years and introduces their advantages and disadvantages, as well as the latest application examples.

Indexed as

Hepatitis BNucleic AcidsGenetic TherapyGenetic VectorsHalf-LifeHumansRNA, Small InterferingNucleic AcidsRNA, Small Interferingbiomedical applicationgene therapynon-viral vectorssiRNA delivery

Identifiers

PMID36834783
PMCPMC9962405
OpenAlexW4319599882

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.